fda warning letters compounding semaglutide september 2025 glp-1 compounded Fda Warning Letters Glp-1 Compounded September 2025 There's lots going on this month at FDA Semaglutide: The Drug of Today

In designing synthetic GLP-1 drugs, pharmaceutical companies outfit the molecules with the capacity to evade breakdown by enzymes

C.ZhaoG

Encourage patients to maintain proper foot hygiene, including bathing, drying, and lubricating the feet

How tirzepatide works Retatrutide belongs to a new generation of experimental metabolic therapies sometimes referred to as triple incretin receptor agonists

Semaglutide and the risk of diabetic retinopathycurrent perspective

Finally, one can foresee a future where combination therapy becomes common: for example, a patient with diabetes and obesity might be on both a GLP-1 RA and an SGLT2 inhibitor (for complementary weight loss and cardio-renal protection, which is already done)